Y. Zhang, L. Zeng, N. Yang, Y. Li Hunan Cancer Hospital, changsha/CN Background: It's reported that crizotinib response duration time differs among ALK-rearranged NSCLC patients with different ALK fusion patterns and detection methods. However inconsistence existed in some available clinical studies and this heterogeneity in first-line crizotinib treatment laking data to elucidate. Method: 80 ALK-rearranged treatment naïve patients received crizotinib form March 2014 to July 2018 in Hunan Cancer Hospital were enrolled in this study for overall survival data analysis. 56 patients underwent NGS detection (Burning Rock, Guang Zhou, 8 gene panel) were included in the analysis of different ALK fusion partners with crizotinib. 24 patients were detected by ventana. PFS of EML4 or non-EML4 variant, single or multiple variant fusion partners and detection methods were also been evaluated. Results: Among all 80 ALK-rearranged patients treated with crizotinib in first-line, 56 patients (70%) were detected by NGS while 24 patients (30%) were identified by ventana. 16 uncommon variants (18/70, 25.7%) which contained 6 novel fusion variants were detected by NGS. Among 56 NGS-identified ALK-rearranged patients, 13 in 56 (23.2%) patients were found with dual fusion partners and 43 in 56 (86.8%) patients were with exclusive ALK fusion partners in which EML4 was the most commom seen (39 in 43). Especially, dual fusion partners were often observed in patients simultaneously detected carrying variant V3 (8 in 13). The overall response rate in all 80 patients was 88.7% and the median progression-free survival time (mPFS) was 12 months. In subroups analysis of different ALK fusion partterns, patients with exclusive ALK fusion pattern were shown to have a longer PFS than those carrying dual ALK fusion patterns. (12m vs. 6.5m, p ¼ 0.02). Comparing with non-EML4 fusion partners, EML4 fusion partners have the longer PFS (12.0m vs. 6.8m, p¼0.04 2 . However, this combination had not been evaluated in the real world, the influential factor of PFS was not sure, and we knew little about the acquired resistance which is of great importance to the subsequent therapy, thus we conducted this study to address these medical needs. Method: A total of 30 advanced EGFR mutant (Del19/L858R) NSCLC patients who received Bevacizumab plus Erlotinib/Gefitinib from March 2014 to July 2017 in Hunan Cancer Hospital were enrolled in this analysis. Clinical information was fully collected. NGS (Burrning rock biotech, 168 genes panel) was applied to detect genetic aberration in both tissue and blood samples, in a dynamic pattern: tissue test before treatment and at progression; blood analysis before treatment, at first radiography evaluation, at the last radiography evaluation before progression and at progression. Results: All patients benefited from this combination. The overall response rate (ORR) was 77% and the median progression survival m(PFS) was 16 months. Neither baseline brain metastasis nor concomitant TP53 mutation shortened PFS (with vs without, 16 m vs 16 m, p¼0.79; 17m vs 13m, p¼0.34) . Of EGFR mutation analysis by NGS, the concordant rate was well enough, 70% (21/30) between the paired initial tissue and blood samples. At progression, T790M was defined as the domain acquired resistance mechanism, contributing 43.8%, followed by MET amplification (12.5%), ERBB2 amplification (6.3%), high abundance of SMAD4 mutation (6.3%). Subgroup analysis showed patients with SMAD4 mutation have shorter PFS compared with those without SMAD4 mutation (10m vs 16m, p¼0.035), while EGFR amplification did not impact PFS (17m vs 16m, p¼0.60). Conclusion: The efficacy of A+T combination was encouraging in the clinical practice and the PFS data 16m in the overall population is consistent with what observed in clinical trials. Patients with baseline brain metastasis & concomitant TP53 and EGFR amplification at progression benefited similar in PFS compared to those without these characters. T790M and MET amplification are the domain acquired resistance mechanism. SMAD4 mutation was regarded as novel resistance mechanism, with PFS shorter than 1 year. We will do a continuous observation on A+T combination in the real world. Reference 1, KATO T, et al. 2014 ASCO Abstract 8005#. 2, Furuya N, et al. 2018 ASCO Abstract 9006#. Keywords: Bevacizumab, EGFR-TKI, Acquired resistance, Next generation sequencing
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